Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
INVO Fertility, Inc., a Nevada-based medical device company with a market capitalization of just $1.13 million, has received a notification from The Nasdaq Stock Market LLC regarding a potential delisting due to the company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The company’s stock has declined over 84% in the past year, according to InvestingPro data. The notice, issued on April 16, 2025, indicates that INVO Fertility is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports.
Despite the warning, INVO Fertility’s common stock continues to trade on The Nasdaq Capital Market under the ticker symbol "NAYA" at $1.92 per share. The company, which InvestingPro data shows has a weak financial health score and concerning current ratio of 0.1, has been given 60 calendar days, until June 15, 2025, to submit a plan to regain compliance. If Nasdaq accepts the company’s plan, it may grant an extension of up to 180 calendar days from the original filing deadline, or until October 13, 2025, to file the overdue report.
INVO Fertility has expressed its intention to file the missing Annual Report as soon as possible to address the issue.
In a separate corporate development, the company announced a name change from its former identity, NAYA Biosciences, Inc., to INVO Fertility, Inc., effective April 14, 2025. This change was executed through an amendment to the Articles of Incorporation filed with the Nevada Secretary of State, which did not require a stockholder vote.
Concurrent with the name change, INVO Fertility plans to change its trading symbol on the Nasdaq Capital Market from "NAYA" to "IVF". The timing for this symbol change is to be announced.
This information is based on a press release statement and the company’s SEC filing. InvestingPro subscribers have access to 8 additional key insights about INVO Fertility, including detailed financial health metrics and valuation analysis that could be crucial for investment decisions.
In other recent news, NAYA Biosciences announced a 1-for-12 reverse stock split of its common stock, effective March 18, 2025. This strategic decision aims to reduce the number of issued and outstanding shares from approximately 7,992,684 to about 666,057, while adjusting authorized shares to 4,166,666 post-split. The move is intended to help the company meet Nasdaq’s minimum $1.00 bid price requirement for continued listing, although compliance is not guaranteed. Additionally, during its 2024 annual meeting, NAYA Biosciences shareholders elected five directors to the Board of Directors, with each director serving until the next annual meeting. The meeting also resulted in the ratification of M&K CPAs PLLC as the independent public accountant for the fiscal year ending December 31, 2024. These developments reflect NAYA’s efforts to align with regulatory standards and strengthen its governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.